Difference between revisions of "CT Angiography Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
m
 
(24 intermediate revisions by 2 users not shown)
Line 1: Line 1:
−
'''Co-chairs''': Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT
+
'''Co-chairs''': Andrew Buckler, MS, PhD; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT
−
'''RSNA Staff Support''': Julie Lisiecki
+
 
 
* [http://tinyurl.com/QIBA-CT-Angiography-Roster Roster]
 
* [http://tinyurl.com/QIBA-CT-Angiography-Roster Roster]
  
Line 8: Line 8:
 
'''Recent Call Summaries:'''
 
'''Recent Call Summaries:'''
  
−
*[[Media: 2019 11 12 QIBA CT Angiography_SME_FINAL-2.pdf | November 12, 2019 (SME call)]]
+
*[[Media:2023_06-27_QIBA_CT_Angiography-FINAL.pdf| June 27, 2023]]
−
*[[Media: 2019 10 30 QIBA CT Angiography_SME_FINAL-2.pdf | October 30, 2019 (SME call)]]
+
*[[Media:2023 03 28 QIBA CT Angiography FINAL.pdf| March 28, 2023]]
−
*[[Media: 2019 10 07 QIBA CT Angiography_FINAL.pdf | October 7, 2019]]
+
*[[Media:2023 03 14 QIBA CT Angiography FINAL.pdf| March 14, 2023]]
−
*[[Media: 2019 09 09 QIBA CT Angiography_FINAL.pdf | September 9, 2019]]
+
*[[Media:2023 02 14 QIBA CT Angiography FINAL.pdf| February 14, 2023]]
−
*[[Media: 2019 08 26 QIBA CT Angiography_FINAL.pdf | August 26, 2019]]
 
−
*[[Media: 2019 08 12 QIBA CT Angiography_FINAL.pdf | August 12, 2019]]
 
−
*[[Media: 2019 07 29 QIBA CT Angiography_FINAL.pdf | July 29, 2019]]
 
−
* Hiatus for public comment period (April - July)
 
−
*[[Media: 2019 04 08 QIBA CT Angiography_FINAL-b.pdf | April 8, 2019]]
 
−
*[[Media: 2019 03 11 QIBA CT Angiography_FINAL-b.pdf | March 11, 2019]]
 
−
*[[Media: 2019 02 25 QIBA CT Angiography_FINAL.pdf | February 25, 2019]]
 
  
 
'''''[[CT Angiography Call Summaries Archive]]'''''
 
'''''[[CT Angiography Call Summaries Archive]]'''''
Line 31: Line 24:
 
==Profile Development==
 
==Profile Development==
  
−
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-11-27-full.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | November 27, 2019]]
+
*[[Media:QIBA CTA Profile as of 2023-Feb-16.pdf|QIBA Atherosclerosis Biomarkers Profile Draft]]
−
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-11-27.PDF | QIBA Atherosclerosis Biomarkers Profile Draft (reduced page count) | November 27, 2019]]
+
*[[Media:QIBA CTA Profile as of 2020-Mar-10.pdf|QIBA Atherosclerosis Biomarkers Profile Draft]]
−
*[[Media:CTA Comments 2019-11-27.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | November 27, 2019]]
+
*[[Media:QIBA CTA Field Test Checklist.xlsx|QIBA Atherosclerosis Checklists]]
 +
*[[Media:Atherosclerosis Biomarkers Profile 2019-11-27-full.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]]
 +
*[[Media:Atherosclerosis Biomarkers Profile 2019-11-27.PDF| QIBA Atherosclerosis Biomarkers Profile Draft (reduced page count)]]
 +
*[[Media:CTA Comments 2019-11-27.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]]
  
−
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-10-30.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | October 30, 2019]]
+
*[[Media:Atherosclerosis Biomarkers Profile 2019-10-30.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]]
−
*[[Media:CTA Comments 2019-10-30.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | October 30, 2019]]
+
*[[Media:CTA Comments 2019-10-30.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]]
  
−
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-09-09b.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | September 9, 2019]]
+
*[[Media:Atherosclerosis Biomarkers Profile 2019-09-09b.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]]
−
*[[Media:CTA Comments 2019-09-09.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | September 9, 2019]]
+
*[[Media:CTA Comments 2019-09-09.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]]
  
−
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-08-26.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | August 26, 2019]]
+
*[[Media:Atherosclerosis Biomarkers Profile 2019-08-26.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]]
−
*[[Media:CTA Comments 2019-08-26.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | August 26, 2019]]
+
*[[Media:CTA Comments 2019-08-26.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]]
  
−
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-08-12.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | August 12, 2019]]
+
*[[Media:Atherosclerosis Biomarkers Profile 2019-08-12.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]]
−
*[[Media:CTA Comments 2019-08-12.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | August 12, 2019]]
+
*[[Media:CTA Comments 2019-08-12.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]]
  
−
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-07-29.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | July 29, 2019]]
+
*[[Media:Atherosclerosis Biomarkers Profile 2019-07-29.PDF| QIBA Atherosclerosis Biomarkers Profile Draft]]
−
*[[Media:CTA Comments 2019-07-29.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | July 29, 2019]]
+
*[[Media:CTA Comments 2019-07-29.xlsx| QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet]]
−
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-02-26.docx | QIBA Atherosclerosis Biomarkers Profile Draft | February 26, 2019]]
+
*[[Media:Atherosclerosis Biomarkers Profile 2019-02-26.docx| QIBA Atherosclerosis Biomarkers Profile Draft]]
−
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-02-11.docx | QIBA Atherosclerosis Biomarkers Profile Draft | February 11, 2019]]
+
*[[Media:Atherosclerosis Biomarkers Profile 2019-02-11.docx| QIBA Atherosclerosis Biomarkers Profile Draft]]
−
*[[Media:2019_01-31_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | January 31, 2019]]
+
*[[Media:2019 01-31 Atherosclerosis Biomarkers Profile-DRAFT.docx| QIBA Atherosclerosis Biomarkers Profile Draft]]
−
*[[Media:2019_01-14_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | January 14, 2019]]
+
*[[Media:2019 01-14 Atherosclerosis Biomarkers Profile-DRAFT.docx| QIBA Atherosclerosis Biomarkers Profile Draft]]
−
*[[Media:2018_12-17_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | December 17, 2018]]
+
*[[Media:2018 12-17 Atherosclerosis Biomarkers Profile-DRAFT.docx| QIBA Atherosclerosis Biomarkers Profile Draft]]
  
 
'''''[[Atherosclerosis Biomarkers Profile Draft Archive]]'''''
 
'''''[[Atherosclerosis Biomarkers Profile Draft Archive]]'''''
Line 60: Line 56:
  
 
==Reference Materials==
 
==Reference Materials==
−
*[[Media:Biomarkers Selection Criteria.pdf | QIBA Biomarkers Selection Criteria Atherosclerosis Biomarker Committee (ABC) {Mr. Buckler}]] ''March 27, 2018'' (PDF)
+
*[[Media:Biomarkers Selection Criteria.pdf| QIBA Biomarkers Selection Criteria Atherosclerosis Biomarker Committee (ABC) {Mr. Buckler}]] ''March 27, 2018'' (PDF)
  
 
==Conformance Materials==
 
==Conformance Materials==

Latest revision as of 18:40, 21 December 2023

Co-chairs: Andrew Buckler, MS, PhD; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT


Meetings

Recent Call Summaries:

CT Angiography Call Summaries Archive

Project Snapshot - CT Angiography

The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA).

Excerpt from the biomarker committee submission form:

The QIBA Atherosclerosis Biomarkers Committee (ABC) is organized to document quantitative profiles for both Computed Tomography Angiography (CTA) and Coronary CTA (CCTA). The membership is composed of participants from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Representatives from different manufacturers are included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee develops technical performance standards to serve as atherosclerosis compositional biomarkers, engaging stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.

Profile Development

Atherosclerosis Biomarkers Profile Draft Archive

Groundwork Projects

Reference Materials

Conformance Materials

Retrieved from "https://qibawiki.rsna.org/index.php?title=CT_Angiography_Biomarker_Ctte&oldid=19476"